Shape's suite of technology platforms broadly enables RNA targeting, RNA editing, and RNA replacement for patients suffering from certain genetic disorders. The company recently announced a breakthrough in RNA delivery with the discovery of next-generation adeno-associated viruses (AAVs) that are central nervous system- or muscle-specific in nonhuman primates.
On the manufacturing front, Shape said it has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods.
The round of series B funding was co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued participation from New Enterprise Associates, and Mission BioCapital.
In addition, Shape announced Min Cui, PhD, founder and managing director at Decheng Capital, will join its board of directors.
Copyright © 2021 scienceboard.net